Comparative effectiveness of an angiotensin receptor blocker, olmesartan medoxomil, in older hypertensive patients
- 20 February 2018
- journal article
- research article
- Published by Wiley in The Journal of Clinical Hypertension
- Vol. 20 (2) , 356-365
Abstract
The efficacy and safety of olmesartan medoxomil (OM) vs active control (AC) monotherapy among elderly patients aged 60‐79 years (N = 4487) was evaluated by meta‐analysis (25 studies). In all patients, change from baseline to end point in blood pressure (BP) was significantly greater with OM vs AC (−19.5/−11.9 vs −16.8/−10.7 mm Hg). Greater proportions of OM‐ vs AC‐treated patients achieved BP goals. In patients with impaired renal function (estimated glomerular filtration rate 2), OM treatment resulted in a greater mean change from baseline in systolic BP vs AC (−21.2 vs −18.7 mm Hg, respectively) and a greater proportion of patients achieving BP goals. These parameters were similar in both groups for elderly patients with diabetes. OM was well tolerated with few adverse events. OM monotherapy can be used as an initial treatment for hypertension in elderly patients, including those with renal impairment or diabetes.Keywords
Funding Information
- Daiichi Sankyo Company
This publication has 35 references indexed in Scilit:
- Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY studyCardiovascular Diabetology, 2012
- ACCF/AHA 2011 Expert Consensus Document on Hypertension in the ElderlyCirculation, 2011
- Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly patients with mild to moderate essential hypertension: the ESPORT studyJournal Of Hypertension, 2010
- Efficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertensionJournal of Human Hypertension, 2010
- Comparison of Olmesartan Medoxomil Versus Amlodipine Besylate on Regression of Ventricular and Vascular HypertrophyThe American Journal of Cardiology, 2009
- Olmesartan Medoxomil in Elderly Patients with Essential or Isolated Systolic HypertensionDrugs & Aging, 2009
- Systolic blood pressure reduction with olmesartan medoxomil versus nitrendipine in elderly patients with isolated systolic hypertensionJournal Of Hypertension, 2007
- Global burden of hypertension: analysis of worldwide dataThe Lancet, 2005
- Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureHypertension, 2003
- Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertensionJournal of Human Hypertension, 2003